Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
5.79
+0.41 (7.62%)
Jan 3, 2025, 4:00 PM EST - Market closed
Orchestra BioMed Holdings Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for OBIO stock have an average target of 15.8, with a low estimate of 14 and a high estimate of 20. The average target predicts an increase of 172.88% from the current stock price of 5.79.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for OBIO stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Initiates $16 | Buy | Initiates | $16 | +176.34% | Jan 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +141.80% | Nov 15, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +245.42% | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +141.80% | Aug 22, 2024 |
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +159.07% | Jul 25, 2024 |
Financial Forecast
Revenue This Year
3.25M
from 2.76M
Increased by 17.57%
Revenue Next Year
3.92M
from 3.25M
Increased by 20.80%
EPS This Year
-1.69
from -1.48
EPS Next Year
-1.99
from -1.69
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 3.5M | 5.3M | 5.3M | |||
| Avg | 3.2M | 3.9M | 3.9M | |||
| Low | 2.7M | 2.7M | 2.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 27.8% | 61.8% | 33.9% | |||
| Avg | 17.6% | 20.8% | -0.3% | |||
| Low | -1.7% | -18.1% | -30.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.73 | -1.81 | -1.67 | |||
| Avg | -1.69 | -1.99 | -1.75 | |||
| Low | -1.64 | -2.05 | -1.80 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.